Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
14.41
+0.12 (0.84%)
Oct 12, 2026, 9:54 AM EDT - Market open
Mesoblast Revenue
In the fiscal year ending June 30, 2026, Mesoblast had annual revenue of $120.25M with 599.21% growth. Mesoblast had revenue of $68.91M in the half year ending June 30, 2026, with 2,640.97% growth.
Revenue (ttm)
$120.25M
Revenue Growth
+599.21%
P/S Ratio
15.52
Revenue / Employee
$1,113,426
Employees
108
Market Cap
1.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 120.25M | 103.05M | 599.21% |
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | 16.72M | -619.00K | -3.57% |
| Jun 30, 2018 | 17.34M | 14.93M | 618.95% |
| Jun 30, 2017 | 2.41M | -40.14M | -94.33% |
| Jun 30, 2016 | 42.55M | 9.79M | 29.88% |
| Jun 30, 2015 | 32.76M | 9.37M | 40.05% |
| Jun 30, 2014 | 23.39M | -8.33M | -26.26% |
| Jun 30, 2013 | 31.72M | -7.41M | -18.93% |
| Jun 30, 2012 | 39.12M | -90.48M | -69.81% |
| Jun 30, 2011 | 129.60M | 128.97M | 20,433.19% |
| Jun 30, 2010 | 631.18K | -89.51K | -12.42% |
| Jun 30, 2009 | 720.69K | -152.06K | -17.42% |
| Jun 30, 2008 | 872.75K | -553.16K | -38.79% |
| Jun 30, 2007 | 1.43M | -669.68K | -31.96% |
| Jun 30, 2006 | 2.10M | 1.71M | 447.74% |
| Jun 30, 2005 | 382.59K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| UroGen Pharma | 188.73M |
| Nuvation Bio | 169.90M |
| Xencor | 104.97M |
| Septerna | 98.88M |
| Intellia Therapeutics | 59.51M |
| Zymeworks | 37.13M |
| Generate Biomedicines | 26.48M |
| Zenas BioPharma | 1.00M |
MESO News
- 18 days ago - Mesoblast receives FDA approval for potency assay to release Ryoncil product - TheFly
- 18 days ago - Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product - GlobeNewsWire
- 6 weeks ago - Mesoblast price target raised to $39 from $35 at Piper Sandler - TheFly
- 6 weeks ago - Full Year 2026 Mesoblast Limited Earnings Presentation Transcript - GuruFocus
- 6 weeks ago - Mesoblast Reports Substantial Revenue Growth to US$120M - GlobeNewsWire
- 6 weeks ago - Mesoblast H2 Earnings Call Highlights - MarketBeat
- 6 weeks ago - Mesoblast Earnings Call Transcript: H2 2026 - Transcripts
- 6 weeks ago - Mesoblast Annual report: H2 2026 - Filings